WallStreetZenWallStreetZen

NASDAQ: ALIM
Alimera Sciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for ALIM

Based on 2 analysts offering 12 month price targets for Alimera Sciences Inc.
Min Forecast
$6.00+69.49%
Avg Forecast
$8.00+125.99%
Max Forecast
$10.00+182.49%

Should I buy or sell ALIM stock?

Based on 2 analysts offering ratings for Alimera Sciences Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ALIM stock forecasts and price targets.

ALIM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-25
lockedlocked$00.00+00.00%2024-03-08

1 of 1

Forecast return on equity

Is ALIM forecast to generate an efficient return?

Forecast return on assets

Is ALIM forecast to generate an efficient return on assets?

ALIM revenue forecast

What is ALIM's revenue in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
$105.9M+31.11%

ALIM vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
ALIM$3.54$8.00+125.99%Strong Buy
LFCR$6.25N/AN/A
OGI$1.88N/AN/A
ZOM$0.14N/AN/A
OPTN$1.19$4.50+278.15%Strong Buy
View Top Pharmaceutical Stocks

Alimera Sciences Stock Forecast FAQ

Is Alimera Sciences Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ALIM) stock is to Strong Buy ALIM stock.

Out of 2 analysts, 1 (50%) are recommending ALIM as a Strong Buy, 1 (50%) are recommending ALIM as a Buy, 0 (0%) are recommending ALIM as a Hold, 0 (0%) are recommending ALIM as a Sell, and 0 (0%) are recommending ALIM as a Strong Sell.

If you're new to stock investing, here's how to buy Alimera Sciences stock.

What is ALIM's revenue growth forecast for 2024-2024?

(NASDAQ: ALIM) Alimera Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.

Alimera Sciences's revenue in 2024 is $80,754,000.

In 2024, ALIM is forecast to generate $5,543,289,166 in revenue, with the lowest revenue forecast at $5,543,289,166 and the highest revenue forecast at $5,543,289,166.

What is ALIM's forecast return on assets (ROA) for 2024-2024?

(NASDAQ: ALIM) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 11.68%.

What is ALIM's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ALIM price target, the average ALIM price target is $8.00, with the highest ALIM stock price forecast at $10.00 and the lowest ALIM stock price forecast at $6.00.

On average, Wall Street analysts predict that Alimera Sciences's share price could reach $8.00 by Mar 25, 2025. The average Alimera Sciences stock price prediction forecasts a potential upside of 125.99% from the current ALIM share price of $3.54.

What is ALIM's forecast return on equity (ROE) for 2024-2024?

(NASDAQ: ALIM) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.